Biological activity is assessed through the protein's binding ability in a functional ELISA utilizing Human VEGI (CAT# cyt-589). The ED50 is determined to be less than or equal to 5ug/ml.
TNFRSF25 is a glycoprotein that is expressed on the surface of various immune cells, including T cells, B cells, and natural killer (NK) cells. The receptor is characterized by the presence of cysteine-rich domains in its extracellular region, which are typical of the TNF receptor superfamily. The intracellular region of TNFRSF25 contains a death domain, which is crucial for the initiation of apoptotic signaling pathways .
The primary function of TNFRSF25 is to mediate apoptosis and regulate immune responses. Upon binding to its ligand, TNFRSF25 can activate several downstream signaling pathways, including the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and the mitogen-activated protein kinase (MAPK) pathway. These signaling pathways play essential roles in cell survival, proliferation, and differentiation .
TNFRSF25 is also involved in the regulation of T helper cell 2 (Th2) effector activity. It co-stimulates the production of interleukin-13 (IL-13) by glycosphingolipid-activated natural killer T (NKT) cells, which is vital for the immune response against certain pathogens .
Recombinant human TNFRSF25 is a laboratory-produced version of the naturally occurring receptor. It is created using recombinant DNA technology, which involves inserting the gene encoding TNFRSF25 into a suitable expression system, such as bacteria or mammalian cells. The recombinant receptor is then purified and used for various research and therapeutic purposes.
Recombinant human TNFRSF25 is widely used in research to study its role in immune regulation and apoptosis. It is also used to investigate the signaling pathways activated by TNFRSF25 and to identify potential therapeutic targets for diseases involving dysregulated apoptosis and immune responses.
In medicine, recombinant human TNFRSF25 has potential therapeutic applications in the treatment of autoimmune diseases, cancer, and other conditions characterized by abnormal immune responses. By modulating the activity of TNFRSF25, it may be possible to restore normal immune function and induce apoptosis in cancer cells .